Clinical Updates on Newborn Screening and Disease Monitoring in Adrenoleukodystrophy is organized by PRIME Education, LLC, National Society of Genetic Counselors (NSGC).

Release Date: October 30, 2020
Expire Date: October 30, 2021

Physician Credit Designation Statement:

PRIME® designates this Enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistant Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Teams:
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Nurse Practitioner Accreditation Statement:
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.5 contact hour (which includes 0.1 hour of pharmacology).

Pharmacist Accreditation Statement:
This Knowledge-based activity has been approved for 0.5 contact hour (0.05 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-20-085-H01-P. Pharmacy CE credits will be submitted electronically to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

Nurse Accreditation Statement:
PRIME® designates this activity for 0.5 contact hour.

Adrenoleukodystrophy (ALD) places a devastating burden on patients and their families. Watch this webcast to hear patients and caregivers speak about the real-world impact of this disease and to learn about current and emerging therapies as well as the latest clinical updates in newborn screening and disease monitoring.